Particularly interesting results with the FAK inhibitor narmafotinib (#AMP945) in advanced pancreatic cancer, also making the popular press this weekend. I note that the FDA has granted Fast Track Designation to #narmafotinib for advanced pancreatic cancer. This will be an interesting space to watch
#Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release tinyurl.com/33ez5srv
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
Amplia Therapeutics Limited
Read and interact with this announcement: Second Complete Response in ACCENT Pancreatic Cancer Trial on Amplia's investor hub
tinyurl.com
July 7, 2025 at 12:54 AM
Particularly interesting results with the FAK inhibitor narmafotinib (#AMP945) in advanced pancreatic cancer, also making the popular press this weekend. I note that the FDA has granted Fast Track Designation to #narmafotinib for advanced pancreatic cancer. This will be an interesting space to watch
I'll be attending next month's AACR Special Conference on Ras Oncogenesis and Therapeutics in Los Angeles to present a poster describing Amplia's preclinical studies of various kRAS inhibitors with our best-in-class FAK inhibitor narmafotinib.
#AACRras26 #FAK #pancreaticcancer
#AACRras26 #FAK #pancreaticcancer
February 19, 2026 at 10:49 PM
I'll be attending next month's AACR Special Conference on Ras Oncogenesis and Therapeutics in Los Angeles to present a poster describing Amplia's preclinical studies of various kRAS inhibitors with our best-in-class FAK inhibitor narmafotinib.
#AACRras26 #FAK #pancreaticcancer
#AACRras26 #FAK #pancreaticcancer
Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease. #business #companies
Fresh data backs Amplia push against pancreatic, ovarian cancer
Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease. #business #companies
www.theage.com.au
July 31, 2026 at 3:16 AM
Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease. #business #companies
Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.07.23.740234v1
July 23, 2026 at 9:57 PM
Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.07.23.740234v1
Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG. #business #companies
Amplia targets ovarian cancer in new clinical protein inhibitor trial
Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG. #business #companies
www.theage.com.au
May 8, 2026 at 4:00 AM
Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG. #business #companies
📢 Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.
Amplia targets ovarian cancer in new clinical protein inhibitor trial
www.theage.com.au
May 8, 2026 at 4:04 AM
📢 Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.
📢 Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease.
Fresh data backs Amplia push against pancreatic, ovarian cancer
www.smh.com.au
July 31, 2026 at 3:21 AM
📢 Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease.
📢 Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.
Amplia targets ovarian cancer in new clinical protein inhibitor trial
www.smh.com.au
May 8, 2026 at 4:04 AM
📢 Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.
Some good news for a change, Australia's Amplia Therapeutics has announced a *2nd* complete response in its trial in advance pancreatic cancer
biotechdispatch.com.au/news/amplia-...
biotechdispatch.com.au/news/amplia-...
Amplia announces second confirmed complete response in ACCENT trial
Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer.
biotechdispatch.com.au
June 19, 2025 at 1:16 AM
Some good news for a change, Australia's Amplia Therapeutics has announced a *2nd* complete response in its trial in advance pancreatic cancer
biotechdispatch.com.au/news/amplia-...
biotechdispatch.com.au/news/amplia-...
Amplia CEO Dr Chris Burns will present at the Life Sciences Virtual Investor Forum this week, sharing recent achievements and next steps in the development of narmafotinib: 3pm Thur 11 December (US ET) / 7am Fri 12 December (AEDT)
🔗 To register: bit.ly/4ptfJHt
#Amplia #pancreaticcancer #FAK
🔗 To register: bit.ly/4ptfJHt
#Amplia #pancreaticcancer #FAK
Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)
Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)
bit.ly
December 10, 2025 at 6:18 AM
Amplia CEO Dr Chris Burns will present at the Life Sciences Virtual Investor Forum this week, sharing recent achievements and next steps in the development of narmafotinib: 3pm Thur 11 December (US ET) / 7am Fri 12 December (AEDT)
🔗 To register: bit.ly/4ptfJHt
#Amplia #pancreaticcancer #FAK
🔗 To register: bit.ly/4ptfJHt
#Amplia #pancreaticcancer #FAK
Amplia and Lilly are dosing a Phase 1b/2b combo trial of narmafotinib and olomorasib in KRAS G12C NSCLC, launching late 2026. Targeting resistance pathways.
Amplia signs Lilly deal to test FAK inhibitor in KRAS G12C lung cancer
Amplia Therapeutics will combine narmafotinib with Lilly's olomorasib in a Phase 1b/2b NSCLC trial starting late 2026, targeting KRAS G12C resistance.
biotech.disruptsmedia.com
August 22, 2026 at 2:00 PM
Amplia and Lilly are dosing a Phase 1b/2b combo trial of narmafotinib and olomorasib in KRAS G12C NSCLC, launching late 2026. Targeting resistance pathways.
Breaking: Eli Lilly's olomorasib gets FDA Breakthrough Therapy designation for advanced pancreatic cancer (Aug 8). Second breakthrough nod for this KRAS G12C inhibitor. Also entering a new combo trial with Amplia's narmafotinib in NSCLC. #ClinicalTrials #PancreaticCancer
corterve.com/trials
corterve.com/trials
August 11, 2026 at 11:02 AM
Breaking: Eli Lilly's olomorasib gets FDA Breakthrough Therapy designation for advanced pancreatic cancer (Aug 8). Second breakthrough nod for this KRAS G12C inhibitor. Also entering a new combo trial with Amplia's narmafotinib in NSCLC. #ClinicalTrials #PancreaticCancer
corterve.com/trials
corterve.com/trials
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
#pancreaticcancer #FAK #olomorasib #narmafotinib
www.globenewswire.com/news-release...
#pancreaticcancer #FAK #olomorasib #narmafotinib
www.globenewswire.com/news-release...
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s...
www.globenewswire.com
August 4, 2026 at 9:20 PM
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
#pancreaticcancer #FAK #olomorasib #narmafotinib
www.globenewswire.com/news-release...
#pancreaticcancer #FAK #olomorasib #narmafotinib
www.globenewswire.com/news-release...
Great write-up of our latest work targeting FAK in pancreatic cancer.
www.theage.com.au/business/com...
#pancreaticcancer #FAK
www.theage.com.au/business/com...
#pancreaticcancer #FAK
Fresh data backs Amplia push against pancreatic, ovarian cancer
Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease.
www.theage.com.au
August 3, 2026 at 3:02 AM
Great write-up of our latest work targeting FAK in pancreatic cancer.
www.theage.com.au/business/com...
#pancreaticcancer #FAK
www.theage.com.au/business/com...
#pancreaticcancer #FAK
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
#pancreaticcancer #FAK
www.globenewswire.com/news-release...
#pancreaticcancer #FAK
www.globenewswire.com/news-release...
www.globenewswire.com
August 2, 2026 at 5:53 AM
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
#pancreaticcancer #FAK
www.globenewswire.com/news-release...
#pancreaticcancer #FAK
www.globenewswire.com/news-release...
📢 Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease.
Fresh data backs Amplia push against pancreatic, ovarian cancer
www.theage.com.au
July 31, 2026 at 3:22 AM
📢 Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease.
Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.07.23.740234v1
July 23, 2026 at 9:57 PM
Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.07.23.740234v1
📢 Amplia Therapeutics has launched a pivotal registration-enabling trial of narmafotinib for pancreatic cancer, testing better efficacy with daily dosing.
Amplia takes aim at billion-dollar pancreatic cancer drug market
www.smh.com.au
May 19, 2026 at 8:54 AM
📢 Amplia Therapeutics has launched a pivotal registration-enabling trial of narmafotinib for pancreatic cancer, testing better efficacy with daily dosing.
Amplia reports updated positive data from ACCENT trial in pancreatic cancer - Biotech - goo.gl/alerts/maByUR #GoogleAlerts
Amplia reports updated positive data from ACCENT trial in pancreatic cancer
Amplia Therapeutics (ASX:ATX) has announced updated data from its ongoing ACCENT clinical trial of its narmafotinib in combination with chemotherapies gemcitabine and abraxane in pancreatic cancer.
goo.gl
May 15, 2025 at 10:36 PM
Amplia reports updated positive data from ACCENT trial in pancreatic cancer - Biotech - goo.gl/alerts/maByUR #GoogleAlerts
Feed: "Business-News-Today.com"
By: Srinath on Sunday, May 31, 2026
By: Srinath on Sunday, May 31, 2026
Amplia Therapeutics (ASX: ATX) stock faces its next big test as narmafotinib moves deeper into cancer trials
Find out how Amplia Therapeutics’ FY2026 report frames ASX: ATX, narmafotinib trials, cash runway and investor sentiment today!
business-news-today.com
May 31, 2026 at 6:18 AM
Feed: "Business-News-Today.com"
By: Srinath on Sunday, May 31, 2026
By: Srinath on Sunday, May 31, 2026
Feed: "Small Caps"
By: Isla Campbell on Friday, May 8, 2026
By: Isla Campbell on Friday, May 8, 2026
Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG
Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.
smallcaps.com.au
May 8, 2026 at 7:34 PM
Feed: "Small Caps"
By: Isla Campbell on Friday, May 8, 2026
By: Isla Campbell on Friday, May 8, 2026
Feed: "Small Caps"
By: Isla Campbell on Tuesday, April 7, 2026
By: Isla Campbell on Tuesday, April 7, 2026
Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs
Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.
smallcaps.com.au
April 8, 2026 at 7:23 AM
Feed: "Small Caps"
By: Isla Campbell on Tuesday, April 7, 2026
By: Isla Campbell on Tuesday, April 7, 2026
Feed: "Small Caps"
By: Imelda Cotton on Wednesday, August 6, 2025
By: Imelda Cotton on Wednesday, August 6, 2025
Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial
Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced
smallcaps.com.au
August 7, 2025 at 2:04 AM
Feed: "Small Caps"
By: Imelda Cotton on Wednesday, August 6, 2025
By: Imelda Cotton on Wednesday, August 6, 2025